Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.

Nature medicine - 1 Jun 2026

Marston Nicholas A, Kany Shinwan, Melloni Giorgio E M, Jurgens Sean J, Kamanu Frederick K, Lai Yi-Pin, Rämö Joel T, Raz Itamar, Wiviott Stephen D, Ellinor Patrick T, Sabatine Marc S, Ruff Christian T

Abstract excerpt

Although the beneficial effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in heart failure (HF) have been well established, it is unknown whether SGLT2 inhibition confers benefit in carriers of rare variants in cardiomyopathy-associated genes. Here we evaluated whole-exome sequencing data from the randomized DECLARE-TIMI 58 trial, in which adults with type 2 diabetes and increased cardiovascular risk...

Topics

Join the communities discussing this publication.

Aged
Benzhydryl Compounds
Cardiomyopathies
Diabetes Mellitus, Type 2
Exome Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 42260102
DOI: 10.1038/s41591-026-04439-x
PMCID: PMC13278951

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.PMID 42260102Read ↗

Assessing the Role of Rare Genetic Variation in Patients With Heart Failure.Semantic proximity Read ↗

Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure.Semantic proximity Read ↗

Whole genome sequencing in early onset advanced heart failure.Semantic proximity Read ↗

Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy.Semantic proximity Read ↗

Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors.Semantic proximity Read ↗

Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure Among Patients with Type 1 DiabetesSemantic proximity Read ↗

Effect of SGLT-2 Inhibitors on Cardiovascular Outcomes Among Patients With Heart Failure and Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis of Randomized Controlled TrialsSemantic proximity Read ↗

Clinical and Genetic Analysis of KATP Variants With Heart Failure Risk in Patients With Decreased Serum ApoA-I Levels.Semantic proximity Read ↗

Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic RiskSemantic proximity Read ↗

Prediction of HF-Related Mortality Risk Using Genetic Risk Score Alone and in Combination With Traditional Risk FactorsSemantic proximity Read ↗

Real-World Effectiveness of SGLT2 Inhibitors Across Heart Failure Phenotypes: A Meta-Analysis.Semantic proximity Read ↗

Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.